Skip header and navigation

10 records – page 1 of 1.

Document Type
Table
Review Code
INF031801v019 RR Table
Question Submitted
March 18, 2021
Date Completed
December 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
for protection against all infections for both non-Delta and Delta variants 2-Nov-21 Immunity pfizer Goldberg Y
Document Type
Table
Review Code
INF031801v019 RR Table
Question Submitted
March 18, 2021
Date Completed
December 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Immunity
Infection Prevention and Control
Clinical Presentation
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Jagwani, M; Lee, S; Shumilak, G; Reeder, B; Groot, G; Hernandez, L; Howell-Spooner, B; Miller, L. How effective are COVID-19 vaccines? 2021 Dec 26; Document no.: INF031801v019 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST Table)
Similar Reviews
EOC011901 RR
EOC031001 RR
Review History
INF031801v17 RR: November 23, 2021
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents

INF031801v019 RR Table

Download File
Less detail
Document Type
Rapid Review
Review Code
INF031801v019 RR
Question Submitted
March 18, 2021
Date Completed
December 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Document Type
Rapid Review
Review Code
INF031801v019 RR
Question Submitted
March 18, 2021
Date Completed
December 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Updated Key Findings
December 14, 2021
Ontario Immunization Advisory Committee recommended that if an 11 and 12-year-old child is inadvertently given a second dose of the Pfizer-BioNTech vaccine that is not authorized for their age, the dose should be considered valid and the series complete.
National Advisory Committee on Immunization (NACI) recommends that a booster dose of an authorized mRNA COVID-19 vaccine should be offered to vulnerable population and > 50 years old, =6 months after completion of a primary COVID-19 vaccine series.
Australian Technical Advisory Group on Immunization (ATAGI) recommends COVID-19 booster vaccination with either Pfizer (Comirnaty) or Moderna (Spikevax), which are considered equally acceptable, for anyone aged 18 and older who completed their primary course of COVID-19 vaccination 5 or more months ago.
On December 8th, 2021 in a press release by Pfizer-BioNTech said that preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 vaccine neutralize the Omicron variant while two doses show significantly reduced neutralization titers. Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses.
Key Findings
December 3, 2021
The Therapeutic Goods Administration (TGA) has granted provisional approval to Moderna for the use of its vaccine in children (two 10µg doses) and as booster shot for adults (one 30µg dose) in preparation for the recent emergence of the Omicron variant. This is in addition to Pfizer, which was also recently approved.
The National Advisory Committee on Immunization (NACI) recommends that a complete series with the Pfizer-BioNTech COVID-19 vaccine (10 mcg) may be offered to children 5-11 years of age who do not have contraindications to the vaccine, with a dosing interval of at least 8 weeks between the first and second dose.
NNACI also recommends that children aged 5-11 years with a history of previous SARS-CoV-2 infection should be considered no longer infectious and symptoms of an acute illness should be completely resolved prior to vaccination.
Health Canada has authorized Moderna's COVID-19 vaccine (also known as Spikevax) to be used as a booster shot, using a half-dose of the vaccine.
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Immunity
Infection Prevention and Control
Clinical Presentation
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Jagwani, M; Lee, S; Shumilak, G; Reeder, B; Groot, G; Hernandez, L; Howell-Spooner, B; Miller, L. How effective are COVID-19 vaccines? 2021 Dec 26. Document no.: INF031801v019 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 93 p. (CEST rapid review report)
Review History
INF031801v17 RR: November 23, 2021
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
INF031801v020 ESR
Question Submitted
March 18, 2021
Date Completed
January 14, 2022
Status
5. Updated review
Research Team
Infectious Disease
; preventing ventilation; preventing “long COVID” (long term symptoms), duration of immunity (natural
Document Type
Evidence Search Report
Review Code
INF031801v020 ESR
Question Submitted
March 18, 2021
Date Completed
January 14, 2022
Status
5. Updated review
Research Team
Infectious Disease
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Infection Prevention and Control
Clinical Presentation
Immunity
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Miller, L., Howell-Spooner, B. How effective are COVID-19 vaccines? 2022 Jan 14, Document no.: INF031801v020 ESR . In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 9 p. (CEST evidence search report).
Review History
INF031801v17 RR: November 23, 2021
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB040803-01 ESR
Question Submitted
April 8, 2020
Date Completed
April 8, 2020
Status
3. Completed
Research Team
Laboratory
1 SUMMARIES, GUIDELINES & OTHER RESOURCES Excerpt from UptoDate Immunity — Antibodies
Document Type
Evidence Search Report
Review Code
LAB040803-01 ESR
Question Submitted
April 8, 2020
Date Completed
April 8, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Testing
Serology
Immunity
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Duncan, V. Is the IgM or IgG immune response protective? 2020 Apr 8; Document no.: LAB040803-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 13 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB040803 RR
Question Submitted
April 8, 2020
Date Completed
April 11, 2020
Status
3. Completed
Research Team
Laboratory
, which is suggestive of protective humoral immunity in COVID-19 patients with mild to moderate symptoms
Document Type
Rapid Review
Review Code
LAB040803 RR
Question Submitted
April 8, 2020
Date Completed
April 11, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Low grade evidence shows IgG and IgM antibody response correlates with neutralizingantibody titerand viral clearance, which is suggestive of protective humoral immunity inCOVID-19 patients with mild to moderate symptoms.
There is no available evidence with which to estimate the durability of this protective response. However, if the immune response to SARS-CoV-2 resembles that toward SARS-CoV, this protective humoral immunity may persist for several years.
Higher IgG antibody titersand a robustresponse were noted in severe to criticallyill patients and were associated with lower viral clearance and a worse clinical prognosis.
Low grade evidence suggests that convalescent plasma treatment may improve the clinical status of critically ill COVID-19 patients(one case series with only five patients enrolled).
Category
Clinical Presentation
Subject
Testing
Serology
Immunity
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Duncan, V; Is the IgM or IgG immune response protective? 2020 Apr 11; Document no.: LAB040803 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 6 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
INF210701 ESR
Question Submitted
July 16, 2021
Date Completed
July 16, 2021
Status
3. Completed
Research Team
Infectious Disease
that a relatively high frequency (99.6%) of humoral immunity was produced in HCWs aged 18-59 after two doses
Document Type
Evidence Search Report
Review Code
INF210701 ESR
Question Submitted
July 16, 2021
Date Completed
July 16, 2021
Status
3. Completed
Research Team
Infectious Disease
Notes
The next update to INF031801's RR will also serve as INF210701's RR
Category
Epidemiology
Infection Prevention and Control
Subject
Risk
Immunity
Vaccines
Infection Prevention and Control
Clinical Presentation
Population
All
Other
travelers, migrants, immigrants, internationals
Clinical Setting
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Miller, L, Howell-Spooner, B. What is known about safety/efficacy of global vaccines not approved in Canada? What are the impacts on international travel and vaccination policies? 2021 Jul 16, Document no.: INF210701 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 24 p. (CEST evidence search report).
Similar Reviews
INF031801*
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
INF090101v3-01 ESR
Question Submitted
September 1, 2020
Date Completed
December 29, 2020
Status
5. Updated review
Research Team
Infectious Disease
QUESTION: What is the duration of immunity for COVID-19 in previously infected patients? UNIQUE
Document Type
Evidence Search Report
Review Code
INF090101v3-01 ESR
Question Submitted
September 1, 2020
Date Completed
December 29, 2020
Status
5. Updated review
Research Team
Infectious Disease
Category
Clinical Presentation
Subject
Immunity
Risk
Population
All adults
Priority Level
Level 5 completed within 2 weeks
Cite As
Young, C; Howell-Spooner, B. What is the duration of immunity for COVID-19 in previously infected patients? 2020 Dec 29; Document no.: INF090101v3-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 39 p. (CEST evidence search report)
Review History
INF090101 RR: September 13, 2020
Related Documents
Documents

INF090101v3-01 ESR

Read PDF Download PDF
Less detail
Document Type
Rapid Review
Review Code
INF090101v2 RR
Question Submitted
September 1, 2020
Date Completed
January 20, 2021
Status
5. Updated review
Research Team
Infectious Disease
Report Review Title: What is the duration of immunity for COVID-19 in previously infected patients
Document Type
Rapid Review
Review Code
INF090101v2 RR
Question Submitted
September 1, 2020
Date Completed
January 20, 2021
Status
5. Updated review
Research Team
Infectious Disease
Key Findings
· First confirmed case of reinfection documented in a 33 year-old man in Hong Kong, who was first infected with the virus in March, and again while on holiday in Spain four and a half months later – though asymptomatic for both infections · Genetic sequencing has identified a small number of reinfection cases with different strains · No concrete evidence on the presence and/or duration of immunity to SARS-CoV-2 in humans · Demonstration of PCR positivity does not necessarily indicate continued or renewed infection; it may indicate the presence of a dead virus. · In-vitro analyses have documented the presence of SARS-CoV-2 antibodies in convalescent samples up to eight months post infection · Only one small study in rhesus monkeys recovered from SARS-CoV-2 were not re-infected when re-challenged with SARS-CoV-2 upon recovery · Many cases series of previously recovered SARS-CoV-2 patients re-testing positive following clinical and pathological recovery, but virus has been unable to be cultured from those patients, most remain asymptomatic and there have been no documented secondary cases arising from patients following positive re-tests
Category
Clinical Presentation
Subject
Immunity
Risk
Population
All adults
Priority Level
Level 5 completed within 2 weeks
Cite As
Badea, A; Lee, S; Groot, G; Takaya, S; Dalidowicz, M; Howell-Spooner, B. What is the duration of immunity for COVID-19 in previously infected patients? 2021 Jan 20; Document no.: INF090101v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 26 p. (CEST rapid review report)
Review History
INF090101 RR: September 13, 2020
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC032401-01 ESR
Question Submitted
March 24, 2020
Date Completed
March 24, 2020
Status
5. Updated review
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC032401-01 ESR
Question Submitted
March 24, 2020
Date Completed
March 24, 2020
Status
5. Updated review
Research Team
EOC
Category
Clinical Presentation
Subject
Immunity
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Dalidowicz, M. What is the risk of reinfection from COVID-19? 2020 Mar 24; Document no.: EOC032401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 3 p. (CEST evidence search report)
Review History
EOC032401v2 RR: August 1, 2020
EOC032401 RR: May 14, 2020
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC032401v3 RR
Question Submitted
March 24, 2020
Date Completed
November 2, 2020
Status
5. Updated review
Research Team
EOC
.2162 Systematic review of immunity and reinfection published to 5/26/2020 - most
Document Type
Rapid Review
Review Code
EOC032401v3 RR
Question Submitted
March 24, 2020
Date Completed
November 2, 2020
Status
5. Updated review
Research Team
EOC
Key Findings
Emerging evidence indicates that there may be a possibility of re-infection with SARS-CoV-2
Several cases with genomic sequencing have found variant strains in re-infection cases
Category
Clinical Presentation
Subject
Immunity
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Badea, A; Lee, S; Shumilak, G; Dalidowicz, M. What is the risk of reinfection from COVID-19? 2020 Nov 2; Document no.: EOC032401v3 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 13 p. (CEST rapid review report)
Review History
EOC032401v2 RR: August 1, 2020
EOC032401 RR: May 14, 2020
Related Documents
Documents
Less detail

10 records – page 1 of 1.